Always consult with a healthcare provider before starting any new treatment or supplementation regimen.
GHK-Cu is not an FDA-approved drug for any indication, and no approved injectable GHK-Cu product exists in any jurisdiction
Primarily used in Eastern Europe, Asia and Russia to improve brain function, memory, and focus as well as to treat brain diseases such as vascular dementia or brain injury
Cagrilintide 2.4 mg plus semaglutide 2.4 mg versus each component alone versus placebo
Optogenetics A versatile, non-invasive neuroscience approach that uses light to accurately regulate neuronal activity, making it the gold standard for circuit studies and a viable tool for creating tailored therapeutics for neurodegenerative illnesses
Therefore, it's unclear if the improvements were due to BPC 157 or simply the passage of time